OFM
BBOT

Omega Fund Management’s BridgeBio Oncology BBOT Stock Holding History

Omega Fund Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.1M Hold
3,289,661
– – 13.5% 4
2026
Q1 		$29.4M Hold
3,289,661
– – 18.05% 3
2025
Q4 		$41.2M Hold
3,289,661
– – 14.37% 2
2025
Q3 		$38.1M Buy
+3,289,661
New +$34.3M 17.13% 3

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Omega Fund Management's BBOT Position: Q2 2026 in Review

Omega Fund Management held its BridgeBio Oncology (BBOT) position steady in Q2 2026 at 3,289,661 shares worth $25.1M. The position accounts for 13.5% of the portfolio, ranked #4.

Omega Fund Management first reported a position in BBOT in Q3 2025 and has held it in 4 quarters since. The position peaked at $41.2M in Q4 2025. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Omega Fund Management held 3,289,661 shares of BridgeBio Oncology worth $25.1M as of Q2 2026.
  • Omega Fund Management left its BridgeBio Oncology share count unchanged in Q2 2026.
  • BridgeBio Oncology made up 13.5% of Omega Fund Management's portfolio in Q2 2026, its #4 holding.
  • Omega Fund Management first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 4 quarters since.
  • Omega Fund Management's BridgeBio Oncology position peaked at $41.2M in Q4 2025.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Omega Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.